Repare Therapeutics Inc
RPTX1.495USD
-0.005-0.33%
交易中 （美東）報價延遲15分鐘
64.12M總市值
虧損本益比TTM
關於 Repare Therapeutics Inc 公司
Repare Therapeutics Inc. 是一家臨牀階段精準腫瘤學公司，通過其專有的合成致死法來發現和開發新型療法。該公司利用其全基因組、支持 CRISPR 的 SNIPRx 平臺系統地發現和開發高度針對性的癌症療法，重點是基因組不穩定性，包括 DNA 損傷修復。其產品線包括 lunresertib (RP-6306)，一種處於 1/2 期臨牀開發的 PKMYT1 抑制劑；camonsertib (RP-3500)，一種潛在的共濟失調毛細血管擴張症和 Rad3 相關蛋白激酶 (ATR) 抑制劑，處於 1/2 期臨牀開發；RP-1664，一種 1 期 PLK4 抑制劑；RP-3467，一種臨牀前聚合酶 θ 腺苷三磷酸酶 (ATPase) 抑制劑項目，以及其他未公開的臨牀前項目。 RP-3500 是一種強效、選擇性口服小分子 ATR 抑制劑，目前正處於臨牀開發階段，用於治療具有特定 DNA 損傷修復相關基因組改變的實體腫瘤。
公司簡介
公司代碼RPTX
公司名稱Repare Therapeutics Inc
上市日期Jun 19, 2020
CEOMr. Steve Forte
員工數量129
證券類型Ordinary Share
年結日Jun 19
公司地址7210 Frederick-Banting, Suite 100
城市ST-LAURENT
上市交易所NASDAQ Global Select Consolidated
國家Canada
郵編H4S 2A1
電話18574127018
網址https://www.reparerx.com/
公司代碼RPTX
上市日期Jun 19, 2020
CEOMr. Steve Forte
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月1日 週五
更新時間: 8月1日 週五
持股股東
股東類型
持股股東
持股股東
佔比
BVF Partners L.P.
24.09%
Blue Owl Capital Holdings LP
7.86%
OrbiMed Advisors, LLC
7.46%
Versant Ventures
6.92%
Redmile Group, LLC
4.39%
Other
49.27%
持股股東
持股股東
佔比
BVF Partners L.P.
24.09%
Blue Owl Capital Holdings LP
7.86%
OrbiMed Advisors, LLC
7.46%
Versant Ventures
6.92%
Redmile Group, LLC
4.39%
Other
49.27%
股東類型
持股股東
佔比
Hedge Fund
27.84%
Investment Advisor/Hedge Fund
15.21%
Investment Advisor
11.59%
Private Equity
7.55%
Venture Capital
6.92%
Individual Investor
1.41%
Research Firm
0.27%
Family Office
0.09%
Other
29.13%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
171
32.21M
75.10%
-8.67M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
2023Q2
203
37.24M
88.48%
-4.72M
2023Q1
213
37.90M
90.09%
-4.89M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BVF Partners L.P.
10.33M
24.09%
--
--
Apr 15, 2025
Blue Owl Capital Holdings LP
3.37M
7.86%
-71.16K
-2.07%
Apr 15, 2025
OrbiMed Advisors, LLC
3.20M
7.46%
-122.13K
-3.68%
Apr 15, 2025
Versant Ventures
2.97M
6.92%
+321.00K
+12.13%
Apr 15, 2025
Redmile Group, LLC
1.88M
4.39%
-31.70K
-1.65%
Mar 31, 2025
Aquilo Capital Management, LLC
1.29M
3.02%
--
--
Mar 31, 2025
MPM Capital Inc.
1.12M
2.61%
-819.92K
-42.24%
Mar 31, 2025
Citadel Advisors LLC
937.49K
2.19%
+937.49K
--
Mar 31, 2025
MPM BioImpact LLC
819.92K
1.91%
-411.23K
-33.40%
Mar 31, 2025
Acadian Asset Management LLC
640.33K
1.49%
+168.23K
+35.63%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
DFA Dimensional US Core Equity Market ETF
0%
Avantis US Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
SPDR S&P International Small Cap ETF
0%
Fidelity MSCI Health Care Index ETF
0%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
ARK Genomic Revolution ETF
0%
查看更多
Invesco Nasdaq Biotechnology ETF
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
DFA Dimensional US Core Equity Market ETF
佔比0%
Avantis US Equity ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
SPDR S&P International Small Cap ETF
佔比0%
Fidelity MSCI Health Care Index ETF
佔比0%
SPDR Portfolio MSCI Global Stock Market ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
ARK Genomic Revolution ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
